MedTrace Logo

Safety and Efficacy of Abatacept in IgG4-Related Disease

NCT03669861 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-24

Study results available
· View outcomes & findings →

Summary

This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks).

Conditions

Interventions

DRUG

Abatacept

Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)

Sponsors & Collaborators

Principal Investigators

  • John H Stone, MD · Massachusetts General Hospital and Harvard Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-13
Primary Completion
2020-04-10
Completion
2020-11-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03669861 on ClinicalTrials.gov